Xiaoli Wang

Xiaoli Wang has extensive work experience in clinical pharmacology and quantitative sciences. They are currently the Head of Clinical Pharmacology and Quantitative Sciences at Nektar Therapeutics since May 2021. Prior to this role, Xiaoli worked as Clinical Pharmacology Oncology at Novartis from April 2018 to April 2021. They also held a position in Clinical Pharmacology and Pharmacometrics at BMS from April 2010 to April 2018. Xiaoli served as an Executive Committee Member at SAPA from 2013 to 2015. Additionally, they worked as Clinical Pharmacology Oncology at Pfizer from 2008 to 2010 and in Clinical Pharmacokinetics and Early Development Services at PRA International from 2006 to 2008.

Xiaoli Wang pursued their education at the University of Florida from 2002 to 2006, where they obtained a Doctorate of Philosophy (Ph.D.) in Pharmaceutical Sciences. Following this, from 2015 to 2018, they attended Rutgers University, where they completed a Master of Business Administration (MBA) degree. The field of study for their MBA program was not specified.